Provided By GlobeNewswire
Last update: Apr 29, 2025
Phase 1a dose-escalation study data update: treatment with NXP900 resulted in exposure levels leading to robust pharmacodynamic responses across a range of tolerated doses; NXP900 has an acceptable safety profile, dose limiting toxicity dose level has not been identified in doses up to 250 mg/day
Read more at globenewswire.comNASDAQ:NVCT (6/12/2025, 2:44:54 PM)
8.945
+0.12 (+1.3%)
Find more stocks in the Stock Screener